Background: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a global pathogen causes wound infection to life-threatening bacteriemia. It causes recalcitrant infections because resistant to various antibiotics. The study focused to assess the efficacy and safety of clindamycin against MRSA infected rats.
Methods: The rats were rendered neutropenic by an intraperitoneal injection of cyclophosphamide injection given for 4 days and 5th day at a dose of 150 mg/kg and 100 mg/kg, respectively. The neutropenic rats were injected subcutaneously with 106 CFU/ml of MRSA. The rats were divided into 3 groups. Normal, Infected, Infected animals treated orally with clindamycin (90 mg/kg/thrice a day) for 14 days. On the 15th day, the abscess size, weight, and bacterial load were measured. The blood and liver were collected for biochemical and histopathological examination.
Results: The MRSA was confirmed by PCR assay. The minimum inhibitory concentration of clindamycin was 0.125 - 0.5 µg/ml. The decreased abscess size, weight, bacterial count, intestinal alkaline phosphatase (IAP), alteration in hematological parameters, mild changes in cholesterol, ALT and liver histology, no significant (P > 0.05) in triglycerides, AST, ALP, bilirubin, lactate, urea, and creatinine were seen in clindamycin treated infected rats. The clindamycin treated infected rats showed mild irritation and diarrhea.
Conclusion: Our study concludes that the clindamycin showed better Anti- MRSA activity and tolerable adverse effects such as anemia, mild irritation after oral treatment, but the intestinal dysbiosis is a severe adverse effect and causes diarrhea.